BioVie has filed an amendment to its September 24, 2024 8-K report regarding a placement agent agreement with ThinkEquity LLC. The original filing detailed the company's plan to issue and sell up to 1,960,800 shares of Class A common stock at $1.53 per share, along with pre-funded warrants at $1.5299 per warrant.The amendment's sole purpose is to include an amended Exhibit 5.1, containing the legal opinion from Fennemore Craig, P.C. The offering package includes Common Warrants to purchase up to 1,960,800 additional shares of Common Stock, with ThinkEquity LLC serving as the placement agent for the transaction.

BioVie has filed an amendment to its September 24, 2024 8-K report regarding a placement agent agreement with ThinkEquity LLC. The original filing detailed the company's plan to issue and sell up to 1,960,800 shares of Class A common stock at $1.53 per share, along with pre-funded warrants at $1.5299 per warrant.The amendment's sole purpose is to include an amended Exhibit 5.1, containing the legal opinion from Fennemore Craig, P.C. The offering package includes Common Warrants to purchase up to 1,960,800 additional shares of Common Stock, with ThinkEquity LLC serving as the placement agent for the transaction.